A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To evaluate the safety and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) using an accelerated dosage schedule; to evaluate duration of antibody response and its relationship to the dose and frequency of inoculation. Although recent advances have been made in antiviral therapy against AIDS, there is currently no cure for AIDS. It is likely that ultimate control of the disease depends on the development of safe and effective vaccines against HIV.

Key facts

Study ID

NCT00000957

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

30

Expected to finish

1993-08-01

Last updated by the study team

2021-11-04

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients must be:
• Normal, healthy, HIV-negative adults who fully comprehend the purpose and details of the study.
• Available for 1 year of follow-up.

You may not qualify if…

• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• They or their sexual partners have identifiable high-risk behavior for HIV infection.
• Positive syphilis serology (e.g., VDRL).
• Positive for circulating hepatitis B antigen.
• Patients with the following prior conditions are excluded:
• History of positive PPD (tuberculin test).
• History of immunodeficiency or chronic illness.
• Evidence of depression or under treatment for psychiatric problems during the past year.
• Prior Medication:
• Excluded:
• Immunosuppressive medications.
• Prior Treatment:
• Excluded:
• Blood transfusions or cryoprecipitates within the past 6 months.
• Risk Behavior: Excluded:
• High-risk behavior for HIV infection.
• History of intravenous drug use.
• More than one sexual partner in the last 6 months.
• Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months.

Where it is running

• St. Louis Univ. School of Medicine AVEG — St Louis, Missouri, United States
• JHU AVEG — Pittsburgh, Pennsylvania, United States
• Vanderbilt Univ. Hosp. AVEG — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.